NCT06120842 - Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution | Biotech Hunter

Enrollment

201

Participants

Timeline

Start Date

October 13, 2023

Primary Completion Date

January 31, 2025

Study Completion Date

November 30, 2027

Conditions

CataractGlaucomaOcular Hypertension

Interventions

DRUG

Bimatoprost Implant System (High Dose)

Bimatoprost Implant System (High Dose) used in combination with the SpyGlass IOL

DRUG

Bimatoprost Implant System (Low Dose)

Bimatoprost Implant System (Low Dose) used in combination with the SpyGlass IOL

DRUG

Timolol Maleate Ophthalmic Solution, 0.5%

Timolol Maleate Ophthalmic Solution 0.5% BID

DEVICE

Commercially Available Aspheric Monofocal Non-Yellow Chromophore IOL

Commercially Available Aspheric Monofocal Non-Yellow Chromophore Intraocular Lens

DEVICE

SpyGlass IOL

SpyGlass Intraocular Lens

Trial Locations (1)

Arizona Advanced Eye Research Institute, Glendale

All Listed Sponsors

lead

SpyGlass Pharma, Inc.

INDUSTRY